A method and composition for the treatment of prostate cancer comprises an
effective amount of a nonsteroidal antiandrogen and an effective amount
of a selective estrogen receptor modulator. The composition has fewer
side effects such as breast tenderness and gynecomastia and also is more
effective as an adjuvant therapy to prevent the reoccurrence of prostate
cancer.